ArticleMolecular and cellular biochemistry2026
Dysregulated KIF2A correlates with p53 expression pattern in breast cancer.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Kinesin family member 2A (KIF2A) and p53 play crucial roles in tumor development and progression. However, their correlation in breast cancer remains unclear. Immunohistochemistry (IHC) was performed on 357 breast cancer specimens to investigate the expression status of KIF2A and p53, their correlations with clinicopathological parameters and prognosis, and their interrelationship in breast cancer. The results demonstrated that KIF2A was highly expressed in breast cancer tissues and exhibited two subcellular localization patterns: nuclear-enriched and cytoplasmic-enriched localization. High KIF2A expression was associated with the human epidermal growth factor receptor 2 (HER2)-positive subtype, lymph node metastasis (LNM), high Ki67 index, and advanced TNM stage, whereas cytoplasmic-enriched localization was associated with higher tumor grade. Both high KIF2A expression and cytoplasmic-enriched localization predicted poor prognosis in patients with breast cancer. A composite index integrating KIF2A expression and localization was an independent prognostic factor. p53 IHC analysis revealed expression pattern categorized as wild-type (57.7%), overexpression (20.4%), and null pattern (21.8%). Abnormal p53 expression (overexpression and null pattern) was associated with LNM, advanced N-stage, high histological grade, estrogen receptor-negative status, progesterone receptor-negative status, HER2-positive status, high Ki67 index, and triple-negative molecular subtypes. Patients with the wild-type, null, and overexpression pattern demonstrated progressively worse prognosis. Additionally, the combined status of KIF2A and p53 IHC could effectively stratify the prognosis of breast cancer. Finally, KIF2A expression was found to be higher in patients with abnormal p53 expression. This study revealed the expression interplay and clinical significance of KIF2A and p53 in breast cancer. The identified association between KIF2A and p53 may provide insights for future research on their roles in breast cancer.
Indexed as
Identifiers
42257979What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.